Table 1 Patient characteristics prior to initiation of intravenous treprostinil treatment

Diagnosis – n (%)

 IPAH/HPAH

38 (70 %)

 PAH-CTD

7 (13 %)

 PAH-CHD

6 (11 %)

 Others*

3 (6 %)

Age at Diagnosis (years)

42 (28–53)

Time from diagnosis to pump implantation (years)

5 (1–10)

Sex – n (%)

 Female

37 (69 %)

 Male

17 (32 %)

BMI

25 (22–28)

Age at implantation (years)

46 (35–60)

Therapy

 Therapeutic anticoagulation – n (%)

27 (50 %)

 LTOT – n (%)

9 (17 %)

 ERA – n (%)

49 (91 %)

 PDE-5-inhibitor – n (%)

40 (74 %)

 Riociguat – n (%)

13 (24 %)

 Iloprost i.v. – n (%)

4 (7 %)

 Iloprost inhaled – n (%)

3 (6 %)

 Treprostinil s.c. – n (%)

0 (0 %)

 Beraprost – n (%)

1 (2 %)

 Selexipag – n (%)

5 (9 %)

Right heart catheter at diagnosis (n = 54)

 Right atrial pressure (mmHg)

9 (6–14)

 PAP mean (mmHg)

57 (47–67)

 PAWP (mmHg)

9 (8–11)

 CO (l/min)

3.4 (3.0-4.3)

 CI (l/min/m²)

2.0 (1.6–2.5)

 PVR (dyn*sec*cm⁵)

961 (739–1311)

 SVI (ml/m²)

25 (21–32)

 Mixed venous oxygen saturation (%)

63 (57–70)